.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Queensland Health
Covington
Boehringer Ingelheim
Julphar
Medtronic
Deloitte
US Army
Dow
Colorcon

Generated: December 17, 2017

DrugPatentWatch Database Preview

SIGNIFOR Drug Profile

« Back to Dashboard

When do Signifor patents expire, and what generic alternatives are available?

Signifor is a drug marketed by Novartis and Novartis Pharms Corp and is included in two NDAs. There are five patents protecting this drug.

This drug has eighty-six patent family members in thirty-nine countries and seventeen supplementary protection certificates in twelve countries.

The generic ingredient in SIGNIFOR is pasireotide pamoate. One supplier is listed for this compound. Additional details are available on the pasireotide pamoate profile page.

Summary for SIGNIFOR

Drug patent expirations by year for SIGNIFOR

Pharmacology for SIGNIFOR

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms CorpSIGNIFOR LARpasireotide pamoatePOWDER;INTRAMUSCULAR203255-003Dec 15, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpSIGNIFOR LARpasireotide pamoatePOWDER;INTRAMUSCULAR203255-003Dec 15, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
Novartis Pharms CorpSIGNIFOR LARpasireotide pamoatePOWDER;INTRAMUSCULAR203255-003Dec 15, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpSIGNIFOR LARpasireotide pamoatePOWDER;INTRAMUSCULAR203255-003Dec 15, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
NovartisSIGNIFORpasireotide diaspartateSOLUTION;SUBCUTANEOUS200677-001Dec 14, 2012RXYesNo► Subscribe► SubscribeYY► Subscribe
Novartis Pharms CorpSIGNIFOR LARpasireotide pamoatePOWDER;INTRAMUSCULAR203255-001Dec 15, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpSIGNIFOR LARpasireotide pamoatePOWDER;INTRAMUSCULAR203255-002Dec 15, 2014RXYesNo► Subscribe► Subscribe► Subscribe
NovartisSIGNIFORpasireotide diaspartateSOLUTION;SUBCUTANEOUS200677-002Dec 14, 2012RXYesNo► Subscribe► Subscribe► Subscribe
NovartisSIGNIFORpasireotide diaspartateSOLUTION;SUBCUTANEOUS200677-001Dec 14, 2012RXYesNo► Subscribe► Subscribe► Subscribe
NovartisSIGNIFORpasireotide diaspartateSOLUTION;SUBCUTANEOUS200677-003Dec 14, 2012RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: SIGNIFOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
NovartisSIGNIFORpasireotide diaspartateSOLUTION;SUBCUTANEOUS200677-001Dec 14, 2012► Subscribe► Subscribe
NovartisSIGNIFORpasireotide diaspartateSOLUTION;SUBCUTANEOUS200677-003Dec 14, 2012► Subscribe► Subscribe
NovartisSIGNIFORpasireotide diaspartateSOLUTION;SUBCUTANEOUS200677-002Dec 14, 2012► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: SIGNIFOR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,939,625Somatostatin analogues► Subscribe
9,035,021Somatostatin analogues► Subscribe
8,822,637Somatostatin analogues► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SIGNIFOR

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)0210192► Subscribe
Russian Federation2355418► Subscribe
Canada2529449► Subscribe
World Intellectual Property Organization (WIPO)2005000893► Subscribe
Australia8977801► Subscribe
BrazilPI0411820► Subscribe
Cyprus1109444► Subscribe
Czech Republic20030288► Subscribe
Argentina044852► Subscribe
Argentina034132► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SIGNIFOR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
12/027Ireland► SubscribePRODUCT NAME: PASIREOTIDE OR A SALT OR COMPLEX THEREOF; REGISTRATION NO/DATE: EU/1/12/753/001-EU/1/12/753/012 20120424
1307486/01Switzerland► SubscribePRODUCT NAME: PASIREOTID; REGISTRATION NO/DATE: SWISSMEDIC 61254 02.11.2012
2012 00024Denmark► Subscribe
0716Netherlands► SubscribePRODUCT NAME: PASIREOTIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/12/753 20141119
024Luxembourg► Subscribe92024, EXPIRES: 20260730
C0041France► SubscribePRODUCT NAME: CYCLO((4R)-4(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-) : PASIREOTIDE, OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/12/753/001 20120424
0120019 00062Estonia► SubscribePRODUCT NAME: SIGNIFOR-PASIREOTIID;REG NO/DATE: C(2012) 2910 FINAL 24.04.2012
00536Netherlands► SubscribePRODUCT NAME: PASIREOTIDE, DESGEWENST IN DE VORM VAN EEN ZOUT, IN HET BIJZONDER PASIREOTIDEDI-ASPARTAAT; REGISTRATION NO/DATE: EU/1/12/753/001-012 20120424
2012 00024Denmark► SubscribePRODUCT NAME: PASIREOTID OG FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER PASIREOTIDDIASPARTAT; REG. NO/DATE: EU/1/12/753/001-012 20120424
8Finland► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Daiichi Sankyo
US Army
AstraZeneca
Cantor Fitzgerald
Medtronic
McKesson
Baxter
Julphar
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot